Abstract
Automated cerebrospinal fluid (CSF) biomarkers have been underexplored in early onset dementias (EOD) within the South-Asian context. In our ongoing ASCEND cohort (tertiary care center in India), we evaluated the added value of incorporating CSF amyloid-β 1-42 (Aβ42) and phosphorylated tau 181 (p-Tau181) (Elecsys immunoassay) into existing clinical diagnostic algorithms for EOD. Among 61 participants (mean age: 56.3 ± 5.8 years; 55.7% females), the CSF p-Tau181/Aβ42 ratio revealed alternative etiology in 16% of cases [5/37 (13.5%) clinically probable AD were reclassified as non-AD after CSF, while 5/24 (20.8%) clinically non-AD dementias were reclassified as AD]. Notably, clinico-biological concordance varied across different phenotypic presentations.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
